Skip to main
  1. Stocks
  2. AIM ImmunoTech Inc
  3. Forecast
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is positioned around a focused late-stage pancreatic cancer strategy, concentrating Ampligen on a disease that still caused more than 100,000 deaths in the American and European Union markets and more than 450,000 worldwide as recently as 2022. The ongoing DURIPANC Phase 2 study, run with AstraZeneca and Erasmus MC, has enrolled 18 subjects and produced an encouraging clinical backdrop, while key data on benefit is expected in Q1 2027 and overall survival in Q3 2027. Fundamentally, the upside thesis is supported by multiple active trials, positive early data, a Q1 2026 net loss of $3.0 million, $6 million in cash against $4 million of debt, and a valuation that appears to understate the potential of its oncology pipeline.

Bears say

AIM ImmunoTech is an early-stage, clinical drug development company with minimal revenue, which leaves it highly dependent on future clinical and regulatory progress rather than recurring commercial cash flow. On August 10, it reported Q2 2026 results showing a $7 million net loss, or $(0.43) per share, materially worse than the $(0.12) to $(0.17) estimates, underscoring weak operating leverage and ongoing cash burn. The negative outlook is driven by balance sheet and liquidity risk, uncertainty around Ampligen and other candidates proving safety and efficacy, and the added difficulty of securing approval, reimbursement, and commercialization in a competitive biotech market.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

AIM Analyst Forecast & Price Prediction

Get the latest AIM stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AIM

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Oct 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


AIM Analyst Forecast & Price Prediction

Get the latest AIM stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AIM

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AIM stock data and trends